- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
M Pharmaceutical Welcomes Douglas Janzen as Senior Clinical Advisor
M Pharmaceutical (CSE:MQ) announced the appointment of life sciences and biotechnology leader Douglas Janzen as Senior Clinical Advisor. Mr. Janzen has more than 20 years of leadership experience in corporate finance, business development and management. He is the Co-Founder and Managing Director of Northview Ventures, and President and CEO of Aequus Pharmaceuticals.
As quoted in the press release:
“We are of course very pleased to have someone of Douglas’s stature and background join us as Senior Clinical Advisor,” said Dr. Martin Mintchev, President and Chief Executive Officer of M Pharmaceutical. “With his leadership reputation in biotechnology, pharma and life sciences and an impressive toolkit in the areas of entrepreneurship, finance and business development, Douglas is bound to deliver significant added value to everything we do in bringing our own innovative biomedical technologies to market.”
Recognized for his passion for life sciences and biotechnology, Janzen serves on the boards of Neovasc, Aequus, Alabaster Technologies, Ico Therapeutics, Perimeter Medical Imaging, Renaissance Biosciences and Synaptive Technologies.
Before founding Northview Ventures, a strategic investment and consulting firm focused on life sciences and high tech, he served nine years as a senior executive at Cardiome Pharma, where he held the leadership positions of Chief Financial Officer (2003 – 2005), President and Chief Business Officer (2005 – 2009), and President and Chief Executive Officer (2009 – 2012).
At Cardiome, Janzen raised over $300 million from investors and completed over $1 billion in licensing deals. He formed the partnership with Merck that brought Cardiome’s flagship product “Brinavess” through to clinical approval and marketing in Europe.
Prior to Cardiome, Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. He has completed over $1 billion in equity financing for Canadian bio-tech companies and has previously served as chair of LifeSciences BC and as a director with Biotech Canada. Janzen is also a former winner of Business in Vancouver’s “Top 40 Under 40 Award”.
Click here to read the M Pharmaceutical (CSE:MQ) press release
Click here to see the M Pharmaceutical (CSE:MQ) profile.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.